ClinTec Expands for Vaccine Development

ClinTec International, a global CRO with a substantial presence in the Middle East and Africa has expanded its operations into Malawi. A top 5 pharmaceutical company with sales exceeding US$50 billion has selected ClinTec as its preferred partner for vaccine development in Africa and Asia, further enhancing ClinTec’s growing presence in the emerging markets of Africa, Asia and the Middle East. The global vaccines market has an estimated value of US$33.8 billion.

Africa is a pivotal region for the development of adult and pediatric vaccines against infectious diseases and ClinTec is well placed to participate in these programs. The company is in the process of recruiting highly skilled personnel with vaccine research experience to join its already established teams in Africa and Asia, in preparation for strong growth ahead from these geographic markets.

Vaccine development faces its own challenges associated with local immunization recommendations as well as stringent cold chain management. ClinTec’s team has the experience and understanding of the local challenges involved in working effectively in Africa and Asia, while complying in full with international clinical research guidelines.